Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 4351 - 4375 of 6076 in total
Experimental
Matched Iupac: … amino-9H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy})phosphinic acid ... 3S,5R)-5-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-2-(hydroxymethyl)oxolan-3-yl]oxy}({[(2R,3S,5R)-5-(6- …
Experimental
Matched Iupac: … (2S,3R)-2-amino-1-[({[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}sulfonyl …
Experimental
Matched Iupac: … {[(2R,3S,4R,5S)-5-(6-amino-7H-purin-7-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}phosphonic acid …
Tocladesine has been used in trials studying the treatment of Colorectal Cancer and Multiple Myeloma and Plasma Cell Neoplasm.
Investigational
Matched Iupac: … (4aR,6R,7R,7aS)-6-(6-amino-8-chloro-9H-purin-9-yl)-2,7-dihydroxy-hexahydro-2lambda5-furo[3,2-d][1,3,2 …
Verpasep caltespen is a recombinant chimeric protein composed of the heat shock protein 65 (Hsp65) from Mycobacterium bovis, and the human papilloma viral (HPV) protein E7. Hsp65, similar to other members of its family of proteins, elicits a strong immune response and may be used to design vaccines against a...
Investigational
Investigational
The Recombinant SARS-CoV-2 Vaccine was created by inserting genes of the SARS-CoV-2 spike protein’s receptor-binding domain into a baculovirus expression system[F4738, A226853]. In pre-clinical trial testing on mice, rabbits, and non-human primates, the candidate was able to induce a functional antibody response within 7-14 days of initial injection . It...
Investigational
Experimental
Matched Iupac: … [({[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)methyl …
Experimental
Investigational
Experimental
Matched Iupac: … (2S,3S)-2-amino-N-({[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl}sulfamoyl …
Experimental
Matched Iupac: … {[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-4-hydroxy-3-(phosphonooxy)oxolan-2-yl]methoxy}phosphonic acid …
Experimental
Matched Iupac: … [({[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)methyl …
Experimental
Matched Iupac: … (2S)-2-amino-1-[({[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}sulfonyl) …
A stable adenosine A1 and A2 receptor agonist. Experimentally, it inhibits cAMP and cGMP phosphodiesterase activity. [PubChem]
Experimental
Matched Iupac: … (2R,3R,4R,5R)-5-(6-amino-9H-purin-9-yl)-N-ethyl-3,4-dihydroxyoxolane-2-carboxamide …
Experimental
Matched Iupac: … (2S)-2-amino-1-[({[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}sulfonyl) …
Experimental
Investigational
Experimental
Matched Iupac: … {[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}({[(2R,3R,4R,5R)-2-(2,4-dioxo …
Experimental
Matched Iupac: … 2-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-[(phosphonooxy)methyl]oxolan-2-yl]-7-methyl-6-oxo-6,9-dihydro …
Giloralimab is under investigation in clinical trial NCT04807972 (Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 Is Administered in Combination With IV Modified FOLFIRINOX (Mffx) With or Without IV Budigalimab Compared to Mffx in Adult Participants With Untreated Pancreatic Cancer Metastasis).
Investigational
Experimental
Matched Iupac: … {[amino(hydroxy)phosphoryl]oxy}({[(2R,3S,4R,5R)-5-(2-amino-6-oxo-6,9-dihydro-3H-purin-9-yl)-3,4-dihydroxyoxolan …
Experimental
Matched Iupac: … oxo-6,9-dihydro-3H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy})phosphinic acid ... oxo-1,2-dihydropyrimidin-1-yl)-4-hydroxy-5-(hydroxymethyl)oxolan-3-yl]oxy}({[(2R,3S,4R,5R)-5-(2-amino-6- …
5'-Adenylic acid, monoanhydride with sulfuric acid. The initial compound formed by the action of ATP sulfurylase on sulfate ions after sulfate uptake. Synonyms: adenosine sulfatophosphate; APS.
Experimental
Investigational
Matched Iupac: … [({[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy] …
Displaying drugs 4351 - 4375 of 6076 in total